• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Clin Med . Elevated TAT in COVID-19 Patients with Normal D-Dimer as a Predictor of Severe Respiratory Failure: A Retrospective Analysis of 797 Pa

tetano

Editor, Senior Moderator
J Clin Med


. 2021 Dec 27;11(1):134.
doi: 10.3390/jcm11010134.
Elevated TAT in COVID-19 Patients with Normal D-Dimer as a Predictor of Severe Respiratory Failure: A Retrospective Analysis of 797 Patients


Yuichiro Takeshita[SUP] 1 [/SUP], Jiro Terada[SUP] 1 2 [/SUP], Yasutaka Hirasawa[SUP] 1 [/SUP], Taku Kinoshita[SUP] 1 [/SUP], Hiroshi Tajima[SUP] 1 [/SUP], Ken Koshikawa[SUP] 1 2 [/SUP], Toru Kinouchi[SUP] 1 2 [/SUP], Yuri Isaka[SUP] 1 2 [/SUP], Yu Shionoya[SUP] 1 [/SUP], Atsushi Fujikawa[SUP] 1 [/SUP], Yuji Tada[SUP] 1 [/SUP], Chiaki Nakaseko[SUP] 3 [/SUP], Kenji Tsushima[SUP] 1 [/SUP]



Affiliations

Abstract

Although previous studies have revealed that elevated D-dimer in the early stage of coronavirus 2019 (COVID-19) indicates pulmonary intravascular coagulation, the state of coagulation/fibrinolysis disorder with normal D-dimer is unknown. The study aimed to investigate how coagulation/fibrinolysis markers affect severe respiratory failure in the early stage of COVID-19. Among 1043 patients with COVID-19, 797 patients were included in our single-center retrospective study. These 797 patients were divided into two groups, the normal D-dimer and elevated D-dimer groups and analyzed for each group. A logistic regression model was fitted for age, sex, body mass index (BMI) ≥ 30 kg/m[SUP]2[/SUP], fibrinogen ≥ 617 mg/dL, thrombin-antithrombin complex (TAT) ≥ 4.0 ng/mL, and plasmin-alpha2-plasmin inhibitor-complex (PIC) > 0.8 µg/mL. A multivariate analysis of the normal D-dimer group demonstrated that being male and TAT ≥ 4.0 ng/mL significantly affected severe respiratory failure. In a multivariate analysis of the elevated D-dimer group, BMI ≥ 30 kg/m[SUP]2[/SUP] and fibrinogen ≥ 617 mg/dL significantly affected severe respiratory failure. The elevated PIC did not affect severe respiratory failure in any group. Our study demonstrated that hypercoagulation due to SARS-CoV-2 infection may occur even during a normal D-dimer level, causing severe respiratory failure in COVID-19.

Keywords: COVID-19; D-dimer; TAT; coagulation; disseminated intravascular coagulation; fibrinolysis; respiratory failure.
 
Back
Top Bottom